KLP Kapitalforvaltning AS Purchases 600 Shares of Repligen Corporation $RGEN

KLP Kapitalforvaltning AS boosted its position in Repligen Corporation (NASDAQ:RGEN) by 5.8% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 11,000 shares of the biotechnology company’s stock after acquiring an additional 600 shares during the quarter. KLP Kapitalforvaltning AS’s holdings in Repligen were worth $1,368,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also added to or reduced their stakes in the company. Alliance Wealth Advisors LLC UT increased its stake in Repligen by 2.5% in the first quarter. Alliance Wealth Advisors LLC UT now owns 3,675 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 89 shares during the last quarter. State of Michigan Retirement System increased its stake in Repligen by 0.8% in the first quarter. State of Michigan Retirement System now owns 12,453 shares of the biotechnology company’s stock valued at $1,585,000 after acquiring an additional 100 shares during the last quarter. Louisiana State Employees Retirement System increased its stake in Repligen by 0.7% in the first quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company’s stock valued at $1,858,000 after acquiring an additional 100 shares during the last quarter. State of Wyoming increased its stake in Repligen by 5.2% in the first quarter. State of Wyoming now owns 2,338 shares of the biotechnology company’s stock valued at $297,000 after acquiring an additional 115 shares during the last quarter. Finally, Signaturefd LLC increased its stake in Repligen by 65.3% in the first quarter. Signaturefd LLC now owns 324 shares of the biotechnology company’s stock valued at $41,000 after acquiring an additional 128 shares during the last quarter. Institutional investors own 97.64% of the company’s stock.

Insider Buying and Selling at Repligen

In other Repligen news, Director Martin D. Madaus bought 1,800 shares of the firm’s stock in a transaction on Friday, August 8th. The stock was acquired at an average price of $112.13 per share, with a total value of $201,834.00. Following the completion of the purchase, the director owned 1,800 shares of the company’s stock, valued at approximately $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 1.20% of the company’s stock.

Analyst Upgrades and Downgrades

RGEN has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d)” rating on shares of Repligen in a research note on Wednesday, October 8th. HSBC began coverage on shares of Repligen in a research report on Wednesday, October 1st. They set a “buy” rating and a $150.00 price target for the company. Jefferies Financial Group cut their price target on shares of Repligen from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, September 12th. Evercore ISI upped their price target on shares of Repligen from $155.00 to $175.00 and gave the company an “outperform” rating in a research report on Tuesday, October 7th. Finally, Royal Bank Of Canada restated an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Tuesday, September 2nd. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $169.62.

Repligen Stock Performance

Shares of RGEN opened at $148.67 on Tuesday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.59 and a quick ratio of 7.32. Repligen Corporation has a one year low of $102.96 and a one year high of $182.52. The company has a 50-day simple moving average of $125.77 and a two-hundred day simple moving average of $125.65. The firm has a market capitalization of $8.36 billion, a PE ratio of -594.66, a price-to-earnings-growth ratio of 2.68 and a beta of 1.08.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, July 29th. The biotechnology company reported $0.37 EPS for the quarter, missing the consensus estimate of $0.40 by ($0.03). Repligen had a positive return on equity of 4.61% and a negative net margin of 2.05%.The company had revenue of $182.37 million during the quarter, compared to analysts’ expectations of $174.62 million. During the same quarter last year, the business earned $0.40 earnings per share. The business’s quarterly revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2025 guidance at 1.650-1.720 EPS. On average, analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Repligen Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.